Peptides for Women: Menopause, Hormones, and What the Research Shows

Evidence-based guide to PT-141, GHK-Cu, GLP-1 agonists, and more

Peptide Portal ResearchEditorial Team

·May 10, 2026·16 min read

Women make up over 40% of the peptide therapy market, yet most educational content focuses on male-centric goals like muscle gain and testosterone optimization. This guide addresses what women actually want to know: Can peptides help with menopause symptoms? What does the research show for libido, skin aging, and stubborn weight gain?

Here's the honest answer: only three peptides have meaningful clinical evidence for women-specific concerns. PT-141 (bremelanotide) is FDA-approved for low sexual desire. Semaglutide and tirzepatide have strong data for weight management, with newer research suggesting they work even better when combined with hormone replacement therapy. GHK-Cu has solid clinical trials showing collagen improvements in women. Everything else falls into the "promising but unproven" category.

This guide breaks down the evidence for each peptide, explains what the research actually demonstrates (not what marketing claims), and covers safety considerations specific to women.

This content is for informational purposes only and is not medical advice. Consult a healthcare provider before using any peptides.

Which Peptides Have Real Evidence for Women?

The peptide landscape is cluttered with hype. Separating what's proven from what's theoretical requires looking at actual human clinical trials, not animal studies or anecdotes.

FDA-approved peptides with women-specific indications:

PT-141 (bremelanotide/Vyleesi) for hypoactive sexual desire disorder
Semaglutide (Wegovy) for weight management
Tirzepatide (Zepbound) for weight management

Peptides with clinical trial data in women:

GHK-Cu for skin collagen and wound healing
Oral collagen peptides for genitourinary syndrome of menopause (pilot study)

Peptides with animal research suggesting women-specific benefits:

MOTS-c for post-menopausal metabolism
Ipamorelin for bone mineral density

Peptides commonly marketed to women but lacking female-specific evidence:

BPC-157 (one small study in women with bladder conditions)
TB-500
Thymosin Alpha-1

Let's examine what the research actually shows for each category.

PT-141 (Bremelanotide): The Only FDA-Approved Peptide for Female Sexual Health

PT-141, sold under the brand name Vyleesi, received FDA approval in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD). This makes it the only peptide with a specific FDA indication for a women's health condition.

What Is HSDD?

HSDD is a persistent lack of sexual desire that causes personal distress and isn't explained by relationship problems, medical conditions, or psychiatric issues. It affects an estimated 10% of premenopausal women.

How PT-141 Works

Unlike medications that increase blood flow, PT-141 works in the brain. It activates melanocortin receptors (MC3R and MC4R), which influence dopamine pathways involved in sexual desire. The effects are central rather than peripheral, meaning it targets wanting rather than physical arousal.

What the Clinical Trials Found

The Phase 3 RECONNECT trials enrolled 1,267 premenopausal women. Results showed:

25% of women treated with PT-141 reported restored sexual desire, compared to 17% on placebo
Significant reduction in distress associated with low desire
Effects lasted 4-6 hours after injection
Onset typically occurs 60-90 minutes post-injection

Long-term data from 2024-2025 show the benefits sustained over 52 weeks without receptor desensitization, which was an early concern.

Side Effects

Nausea is the most common adverse event, occurring in about 40% of treated patients versus 13% on placebo. Other side effects include:

Flushing (20%)
Headaches (10-15%)
Injection site reactions

These typically subside quickly, but nausea can be significant for some women.

Dosing and Limitations

The FDA-approved dose is 1.75mg subcutaneous injection into the abdomen or thigh, taken 45 minutes before anticipated sexual activity. Patients are limited to one dose per 24 hours and a maximum of eight doses per month.

PT-141 is approved only for premenopausal women. Research in postmenopausal women is limited, though some practitioners prescribe it off-label.

The Bottom Line on PT-141

PT-141 has legitimate clinical trial support for HSDD in premenopausal women. The 8 percentage point improvement over placebo is statistically significant but modest. It works for some women and not others. The nausea can be a dealbreaker. But for women who have tried other options without success, the evidence supports it as a reasonable option to discuss with a provider.

Weight Management: GLP-1 Agonists and the Menopause Connection

Weight gain during perimenopause and menopause is one of the most common complaints women bring to their doctors. The hormonal shifts of menopause, particularly declining estrogen, contribute to changes in fat distribution, insulin sensitivity, and metabolism.

Semaglutide and Tirzepatide: What the Research Shows

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved GLP-1 receptor agonists with strong evidence for weight loss. While not developed specifically for menopausal women, recent research suggests they may be particularly effective in this population when combined with hormone therapy.

The Tirzepatide + HRT Study (2026):

A study published in The Lancet Obstetrics, Gynaecology, & Women's Health by researchers at Mayo Clinic and Wayne State University found that postmenopausal women using both tirzepatide and hormone therapy lost 35% more weight than those using tirzepatide alone.

After 15 months:

Women on tirzepatide + HRT: 17% total body weight loss
Women on tirzepatide alone: 14% total body weight loss
45% of HRT users achieved at least 20% weight loss, versus 18% of non-users

The Semaglutide + HRT Study (2024):

An earlier study found similar synergy. Postmenopausal women using semaglutide with HRT lost 16% of body weight after 12 months, compared to 12% for women on semaglutide without HRT. That's a 30% relative difference.

Why Might HRT Enhance GLP-1 Medications?

Researchers have a few theories. Estrogen appears to enhance the body's natural GLP-1 signaling system, based on rodent studies. Menopause hormone therapy also improves insulin sensitivity, adaptive thermogenesis, and fat distribution. It may also relieve symptoms like sleep disruption and hot flashes that make weight loss harder.

Important Caveats

These were observational studies, not randomized trials. Women who choose HRT may already be more engaged in their health. They may sleep better, exercise more, or make different dietary choices. The correlation doesn't prove HRT causes additional weight loss.

Prospective, randomized controlled trials are needed to establish causality. For now, the evidence suggests the combination may be synergistic, but more research is required.

Oral GLP-1 Options in 2026

In April 2026, the FDA approved orforglipron (Foundayo), the first small-molecule oral GLP-1 medication for weight loss. An oral version of semaglutide was approved in December 2025. These expand options for women who prefer pills over injections.

GHK-Cu: The Skin Peptide with Real Clinical Data

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring peptide that declines with age. It has more clinical trial evidence for skin benefits than most peptides on the market.

What GHK-Cu Does

GHK-Cu affects about 31% of human genes, either activating or deactivating them through epigenetic mechanisms. In skin, it:

Stimulates collagen production
Increases elastin synthesis
Promotes wound healing
Reduces inflammation

Clinical Trial Results in Women

The McGill University Trial (2023):

A study conducted by Wayne Carey, MD, Professor of Dermatology at McGill University, evaluated 21 women using pre- and post-treatment ultra-high resolution ultrasound imaging.

Results after 3 months of daily application:

Average 28% increase in collagen density
Top quartile of responders showed 51% improvement
No significant adverse effects reported

Facial Aging Study:

A study of 71 women with mild to advanced photoaging found that after 12 weeks of GHK-Cu facial cream application:

Improved skin laxity
Reduced fine lines and wrinkle depth
Increased skin density and thickness
Improved skin clarity

Comparison to Other Actives:

A study comparing collagen production in women around age 50 found:

70% of women treated with GHK-Cu showed increased collagen
50% treated with vitamin C cream showed increases
40% treated with retinoic acid showed increases

Wrinkle Reduction:

In a randomized, double-blind trial of 40 women aged 40-65, GHK-Cu delivered via nano-lipid carrier reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% over eight weeks.

How to Use GHK-Cu

GHK-Cu is available in topical formulations (serums, creams) and injectable forms. The clinical trials showing skin benefits used topical application. Injectable GHK-Cu is sometimes marketed for systemic anti-aging effects, but the evidence base for that route is weaker.

For skin benefits, topical application is the evidence-supported choice.

Growth Hormone Secretagogues: Ipamorelin and CJC-1295

Growth hormone secretagogues like ipamorelin and CJC-1295 stimulate the body's natural growth hormone release. They're popular in anti-aging circles, but what does the evidence show for women specifically?

Ipamorelin

Ipamorelin is considered one of the most selective growth hormone releasing peptides. Unlike older GH secretagogues, it doesn't significantly affect cortisol or prolactin levels, giving it a cleaner side effect profile.

Research in Female Subjects:

A study in female rats found that 12 weeks of ipamorelin treatment increased bone mineral content and bone dimensions. This has implications for osteoporosis prevention, though human trials in women are lacking.

Another study in mice found that ipamorelin's metabolic effects were more pronounced in females than males, though this was animal research.

CJC-1295

CJC-1295 is a growth hormone releasing hormone (GHRH) analog often combined with ipamorelin. The "CJC-1295 + Ipamorelin stack" is commonly prescribed for anti-aging purposes.

The Evidence Gap

Here's the problem: there are no published randomized controlled trials of ipamorelin or CJC-1295 specifically studying menopausal women. The claims about improved body composition, sleep, and energy are based on:

General growth hormone physiology
Animal studies
Small uncontrolled human studies
Clinical observation

These peptides are not FDA-approved for any indication. They're available through compounding pharmacies under physician supervision, but the evidence supporting their use in women is limited.

Should Women Consider Them?

Some women report benefits from GH secretagogues, including better sleep, improved skin quality, and easier body composition management. But without controlled trials, it's impossible to separate real effects from placebo response. If you're considering these peptides, work with a knowledgeable provider who can monitor IGF-1 levels and watch for side effects like water retention and joint discomfort.

MOTS-c: The Mitochondrial Peptide

MOTS-c is a mitochondrial-derived peptide that's generated significant research interest for metabolic health and aging. It may have particular relevance for postmenopausal women.

The Menopause Connection

Research suggests MOTS-c levels decline with age, and this decline may be accelerated after menopause. In premenopausal women, estrogen appears to have protective effects on mitochondrial function that may preserve MOTS-c levels.

Animal Research:

Studies in ovariectomized mice (a model for menopause) found that MOTS-c administration:

Reduced fat accumulation in white adipose tissue and liver
Increased brown fat activation
Improved insulin sensitivity

Interestingly, MOTS-c didn't change metabolic markers in female mice with normal hormonal function, but it improved metabolic function in ovariectomized mice. This suggests it may specifically address metabolic dysfunction that accompanies estrogen loss.

Human Research Status

MOTS-c is the first mitochondrial-encoded peptide to enter clinical trials. However, clinical development has stagnated due to challenges with:

Low bioavailability
Poor stability
Short half-life

As of 2026, MOTS-c is not available as a reliable therapeutic. It's primarily of research interest.

BPC-157: Overhyped for Women's Health

BPC-157 is frequently marketed for healing and recovery, but its evidence base for women-specific applications is thin.

The Only Study in Women

In 2024, a pilot study treated 12 women with severe interstitial cystitis (painful bladder syndrome) with BPC-157 injections into the bladder wall. Ten of twelve reported complete symptom resolution, and the other two reported 80% improvement.

However, this was not a controlled trial. There was no placebo group. The impressive results could reflect placebo effect or the invasive procedure itself.

Regulatory Status

BPC-157 is not FDA-approved. Following FDA restrictions in 2024, it was largely unavailable through US compounding pharmacies. In February 2026, HHS announced plans to return several peptides, including BPC-157, to compounding eligibility, pending an advisory panel review in July 2026.

Should Women Use BPC-157?

Despite decades of promising animal research, human clinical data remains extremely limited. Only three published human studies exist as of 2026, all pilot studies with small sample sizes. No randomized controlled trials exist.

Women considering BPC-157 should understand they're essentially participating in an uncontrolled experiment. The doses people use are extrapolated from animal studies, not based on human pharmacokinetic data.

Safety Considerations for Women

Peptide therapy carries specific considerations for women that aren't always discussed.

Absolute Contraindications

Pregnancy and Breastfeeding: This is an absolute contraindication for all therapeutic peptides. No safety data exists for fetal effects. Women planning pregnancy should discontinue peptides at least 30 days before attempting conception. Some practitioners recommend 3 months.

GLP-1 Medications and Fertility: An unexpected issue has emerged with semaglutide and tirzepatide. Because these medications can restore regular ovulation in women with polycystic ovary syndrome or obesity-related anovulation, many women have experienced unplanned pregnancies. If you're using GLP-1 medications and don't want to become pregnant, use reliable contraception. Animal studies have shown adverse outcomes in offspring exposed to GLP-1 agonists during pregnancy.

Hormone-Sensitive Conditions

Peptides that affect hormonal signaling require careful evaluation in women with:

History of hormone-sensitive cancers (breast, ovarian, uterine)
BRCA gene mutations
Strong family history of hormone-sensitive cancers

TB-500 in particular requires caution in women with BRCA mutations due to its growth-promoting properties. While no direct cancer link has been established, careful screening is warranted.

Growth-promoting peptides (GH secretagogues, TB-500) warrant cancer screening before initiation in women over 50.

Menstrual Cycle Effects

Women metabolize certain peptides differently than men due to hormonal fluctuations. Some women report changes in menstrual patterns, ovulation, or uterine lining with peptide use. Women with PCOS, insulin resistance, or thyroid conditions may be at higher risk for these effects.

Drug Interactions

Peptides can interact with:

Birth control pills
Hormone replacement therapy
Thyroid medications
Diabetes medications

Always inform your healthcare provider about all peptides you're using.

Key Takeaways

PT-141 (Vyleesi) is the only FDA-approved peptide for a women-specific indication (HSDD in premenopausal women). It works for some women, not all, and nausea is a significant side effect.
GLP-1 agonists (semaglutide, tirzepatide) have strong evidence for weight management and may work better in combination with HRT for postmenopausal women, though more research is needed.
GHK-Cu has legitimate clinical trial evidence for improving skin collagen and reducing wrinkles in women. Topical application is the evidence-supported route.
Growth hormone secretagogues like ipamorelin lack human trials specifically in women. Benefits are theoretical based on general GH physiology.
MOTS-c shows promise for post-menopausal metabolic health but isn't available as a reliable therapeutic.
BPC-157 has almost no human data in women and should be considered experimental.
Pregnancy is an absolute contraindication for all peptide therapies.

Frequently Asked Questions

Can peptides replace hormone replacement therapy for menopause?

No. Peptides and HRT work through completely different mechanisms. HRT directly replaces declining estrogen and progesterone. Peptides target downstream effects like weight gain, skin changes, or libido issues. Some research suggests combining peptides (like GLP-1 agonists) with HRT may be more effective than either alone, but peptides don't address the primary hormonal cause of menopause symptoms.

Is PT-141 effective for postmenopausal women?

PT-141 (Vyleesi) is FDA-approved only for premenopausal women. Research in postmenopausal women is limited. Some practitioners prescribe it off-label for postmenopausal HSDD, but the evidence base is weaker than for premenopausal use.

Are peptides safe during perimenopause?

Safety depends on the specific peptide. FDA-approved peptides like semaglutide and PT-141 have established safety profiles. Research peptides like BPC-157 or MOTS-c lack long-term human safety data. Pregnancy must be ruled out and reliable contraception used, as some peptides can restore fertility in women with anovulation.

How long does it take for GHK-Cu to improve skin?

Clinical trials showed measurable collagen improvements after 3 months of daily topical application. Some wrinkle reduction was observed as early as 8 weeks. Individual results vary based on age, skin condition, and product formulation.

Which peptides help with menopause weight gain?

Semaglutide and tirzepatide have the strongest evidence. Recent research suggests they may be more effective when combined with hormone therapy. MOTS-c shows promise in animal models for post-menopausal metabolic dysfunction, but it's not available as a reliable therapeutic.

Conclusion

The peptide market promises solutions for nearly every menopause-related complaint. The reality is more nuanced. Only a handful of peptides have clinical evidence specifically relevant to women: PT-141 for sexual desire, GLP-1 agonists for weight, and GHK-Cu for skin.

For everything else, women are essentially early adopters participating in real-world experiments. That's not necessarily wrong if you go in with clear expectations and proper medical supervision. But the marketing often outpaces the evidence.

Work with a knowledgeable provider who can help you weigh realistic benefits against unknown risks. Prioritize FDA-approved options where they exist. And approach the peptide landscape with healthy skepticism.

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.

Sources

Weight LossGLP-1Anti-AgingGHK-CuWomen's HealthMenopausePT-141HormonesLibido

Written by

Peptide Portal Research

Editorial Team

Our research team combines expertise in biochemistry, pharmacology, and clinical research to deliver evidence-based content on peptide science.

PhD BiochemistryClinical Research

Last updated May 10, 2026